CN117222665A - 具有改善的稳定性的抗tslp fab - Google Patents

具有改善的稳定性的抗tslp fab Download PDF

Info

Publication number
CN117222665A
CN117222665A CN202280029099.0A CN202280029099A CN117222665A CN 117222665 A CN117222665 A CN 117222665A CN 202280029099 A CN202280029099 A CN 202280029099A CN 117222665 A CN117222665 A CN 117222665A
Authority
CN
China
Prior art keywords
fab
tslp
amino acid
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280029099.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·W·科尔贝克
E·S·科恩
C·E·亨廷顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN117222665A publication Critical patent/CN117222665A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280029099.0A 2021-04-19 2022-04-19 具有改善的稳定性的抗tslp fab Pending CN117222665A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (1)

Publication Number Publication Date
CN117222665A true CN117222665A (zh) 2023-12-12

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280029099.0A Pending CN117222665A (zh) 2021-04-19 2022-04-19 具有改善的稳定性的抗tslp fab

Country Status (19)

Country Link
US (1) US20240199730A1 (https=)
EP (1) EP4326767A1 (https=)
JP (1) JP2024516962A (https=)
KR (1) KR20230172508A (https=)
CN (1) CN117222665A (https=)
AR (1) AR125379A1 (https=)
AU (1) AU2022263281A1 (https=)
BR (1) BR112023021587A2 (https=)
CA (1) CA3216894A1 (https=)
CL (1) CL2023003082A1 (https=)
CO (1) CO2023015286A2 (https=)
CR (1) CR20230533A (https=)
EC (1) ECSP23086870A (https=)
IL (1) IL307651A (https=)
MX (1) MX2023012266A (https=)
PH (1) PH12023552762A1 (https=)
SA (1) SA523451188B1 (https=)
TW (1) TW202306982A (https=)
WO (1) WO2022223514A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202529811A (zh) 2024-01-29 2025-08-01 瑞典商阿斯特捷利康公司 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2024516962A (ja) 2024-04-18
MX2023012266A (es) 2023-10-24
TW202306982A (zh) 2023-02-16
CL2023003082A1 (es) 2024-04-19
EP4326767A1 (en) 2024-02-28
CO2023015286A2 (es) 2024-02-05
BR112023021587A2 (pt) 2023-12-19
SA523451188B1 (ar) 2025-06-22
KR20230172508A (ko) 2023-12-22
AR125379A1 (es) 2023-07-12
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
IL307651A (en) 2023-12-01
PH12023552762A1 (en) 2024-04-15
AU2022263281A1 (en) 2023-11-09
US20240199730A1 (en) 2024-06-20
ECSP23086870A (es) 2023-12-29
WO2022223514A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
US20240199730A1 (en) An anti-tslp fab with improved stability
CN111269315B (zh) 针对bcma的单克隆抗体
US11673950B2 (en) ILT7 binding molecules and methods of using the same
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
TW201206955A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
CN112654640A (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN112996815B (zh) 人pd-l1抗体
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
WO2023046093A1 (zh) 一种双特异性多肽复合物
EP4660205A1 (en) Multiple antibodies against human il-36r and/or human il-1r3, and uses thereof
CN114605539B (zh) 人源化的抗IL-4Rα单域抗体及其应用
EP3891180B1 (en) Humanised anti-il17br antibody
CN115894693A (zh) Trbc1抗体及其应用
WO2023046116A1 (zh) 一种白介素15及其受体的多肽复合物
EA052142B1 (ru) Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
US20230279092A1 (en) Immunocytokines for treatment of autoimmune and inflammatory conditions
CN115340604A (zh) Tim-3全人源单克隆抗体及其应用
BR112018067951B1 (pt) Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos
BR122024004758A2 (pt) Método de produção de um anticorpo anti-ilt7 e anticorpo produzido pelo método, e uso do mesmo
CN1380340A (zh) 重组乙肝病毒免疫球蛋白
NZ624583B2 (en) Antibody molecules having specificity for human ox40

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination